Breaking news on Genetics & Genomics business, policy & funding.
The Series A financing will go toward expanding access to its liquid biopsy-based test to more patients in Asia and North America, it said.
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology response, and the FDA clearance includes no therapeutic indications.
The Ithaca, New York-based firm has submitted its molecular diagnostic instrument along with a test to detect chlamydia, gonorrhea, and trichomonas.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
The amounts to be purchased of each of six separate classes of notes will be determined in accordance with the acceptance priority level determined by Roche.
A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.
LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.
The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.
In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.